Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Smoking Cessation 1Motor Activity 1Lung Neoplasms 1Inflammation 1

Interventions

pembrolizumab 589Cyclophosphamide 539Magnetic Resonance Spectroscopy 523Radiotherapy 506Specimen Handling 503Nivolumab 407Cisplatin 370Carboplatin 358Biopsy 304Blood Specimen Collection 295Radiosurgery 283Paclitaxel 274Surveys and Questionnaires 268Standard of Care 266Gemcitabine 265fludarabine 261Dexamethasone 258Drug Therapy 256venetoclax 246Bevacizumab 246Oxaliplatin 206Rituximab 195Capecitabine 194Radiation 189Fluorouracil 186Ipilimumab 184durvalumab 180Doxorubicin 175atezolizumab 172Etoposide 171

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × cytisine × 1 year × Clear all
NCT03654105 2026-03-27

SMILE

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Active not recruiting
2,000 enrolled
Thoracic

Inflammation, Lung Neoplasms, Motor Activity, Smoking Cessation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡